leadf
logo-loader
viewSareum Holdings PLC

Sareum Holdings says it is close to winning US patent protection for cancer immunotherapy programme

Subject to certain formalities, the company expects the patent will be granted within the next three months

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR) said the US Patent and Trademark Office has issued what is called a notice of allowance offering protection for its pre-clinical cancer immunotherapy drug candidate.

The patent will protect the SDC-1802 molecule and its pharmaceutical preparation.

SDC-1802 is a dual tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor. TYK2 and JAK1 are members of the Janus Kinase (JAK) family of protein kinase enzymes that play roles in autoimmune diseases and tumour cell proliferation in cancer.

In  statement, Dr John Reader, Sareum's chief scientific officer, said: "The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets.

“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company's negotiating position as it continues to engage in discussions with potential licence partners."

Quick facts: Sareum Holdings PLC

Price: 2.3599 GBX

AIM:SAR
Market: AIM
Market Cap: £76.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read